Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. VistaGen Therapeutics's tangible book value per share for the quarter that ended in Dec. 2021 was $0.39.
Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.
VistaGen Therapeutics Tangible Book per Share Historical Data
The historical data trend for VistaGen Therapeutics's Tangible Book per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
VistaGen Therapeutics Annual Data
Trend
Mar12
Mar13
Mar14
Mar15
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Tangible Book per Share
0.07
0.30
0.17
-0.12
0.51
VistaGen Therapeutics Quarterly Data
Mar17
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Tangible Book per Share
0.68
0.51
0.45
0.41
0.39
Competitive Comparison
For the Biotechnology subindustry, VistaGen Therapeutics's Tangible Book per Share, along with its competitors' market caps and Tangible Book per Share data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VistaGen Therapeutics Tangible Book per Share Distribution
For the Biotechnology industry and Healthcare sector, VistaGen Therapeutics's Tangible Book per Share distribution charts can be found below:
* The bar in red indicates where VistaGen Therapeutics's Tangible Book per Share falls into.
VistaGen Therapeutics Tangible Book per Share Calculation
VistaGen Therapeutics's Tangible Book Value Per Share for the fiscal year that ended in Mar. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.
VistaGen Therapeutics (NAS:VTGN) Tangible Book per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
VistaGen Therapeutics Tangible Book per Share Related Terms
Thank you for viewing the detailed overview of VistaGen Therapeutics's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0(0%) Volume: 927,695 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VTGN has been successfully added to your 
